| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | C1QG; C1Q-C |
| Entrez GeneID | 714 |
| clone | 4H9D7 |
| WB Predicted band size | 25.7kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human C1QC (AA: 115-245) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇关于RIOX2(MINA53)抗体的虚构参考文献示例，基于相关领域常见研究主题的合理推测：
---
1. **文献名称**：*RIOX2/MINA53 overexpression correlates with poor prognosis in colorectal cancer by promoting ribosomal RNA methylation*
**作者**：Yamato, T. et al.
**摘要**：本研究利用RIOX2特异性抗体进行免疫组化分析，发现结直肠癌组织中RIOX2蛋白表达显著升高，且与患者生存率负相关。机制研究表明，RIOX2通过催化28S rRNA的甲基化修饰，增强核糖体翻译效率，促进肿瘤增殖。
2. **文献名称**：*A monoclonal antibody-based assay reveals MINA53 as a nucleolar oxygenase regulating histone demethylation*
**作者**：Schofield, C.J. et al.
**摘要**：通过开发高特异性RIOX2单克隆抗体，本研究证实RIOX2定位于细胞核仁，并依赖其JmjC结构域调控组蛋白H3K36me2的去甲基化，影响细胞周期进程及DNA损伤修复。
3. **文献名称**：*RIOX2 antibody-mediated depletion identifies its role in embryonic stem cell pluripotency maintenance*
**作者**：Zhang, L. et al.
**摘要**：利用RIOX2抗体进行功能阻断实验，发现RIOX2通过调控氧化应激相关基因(如Nrf2)的表观遗传修饰，维持胚胎干细胞的自我更新能力，敲低后导致分化异常。
---
**注**：以上文献为示例性质，实际文献需通过数据库(如PubMed)以“RIOX2”、“MINA53”及“antibody”等关键词检索获取。若需真实文献，建议补充具体研究背景或应用场景。
The RIOX2 (RIBOXYLIN 2) antibody targets the RIOX2 protein, also known as MINA53 (MYC-induced nuclear antigen 53), a member of the JmjC-domain-containing histone demethylase family. Discovered as a MYC-responsive gene, RIOX2 is implicated in regulating ribosomal RNA (rRNA) processing and epigenetic modifications. It localizes to the nucleolus and plays roles in cell proliferation, differentiation, and tumorigenesis. Structurally, RIOX2 contains a conserved JmjC domain, enabling its hydroxylase activity, which influences histone H3K9 methylation and ribosomal biogenesis.
RIOX2 overexpression is observed in various cancers (e.g., colorectal, lung, and hepatocellular carcinomas), correlating with poor prognosis. Its oncogenic role involves promoting cell cycle progression, inhibiting apoptosis, and enhancing metastasis. The RIOX2 antibody is essential for detecting protein expression in tissues or cell lines via techniques like Western blotting, immunohistochemistry, or immunofluorescence. Researchers utilize it to explore RIOX2's functional mechanisms, its interaction with MYC signaling, and its potential as a therapeutic target. Commercial antibodies are typically validated for specificity using knockout cell lines or siRNA-mediated silencing. Ongoing studies focus on elucidating RIOX2's role in epigenetic regulation and cancer biology, aiming to develop inhibitors for clinical applications.
×
